Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older

NCT06907511 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

720

Enrollment

INDUSTRY

Sponsor class

Conditions

Pandemic Influenza Immunization
Healthy Volunteers

Interventions

BIOLOGICAL: Pandemic flu H5 HA mRNA SD2 vaccine
OTHER: Placebo

Sponsor

Sanofi